Citadel Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Citadel Advisors’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$764K	Sell	71,032 -82,578	-54%	-$674K	﹤0.01%	8863
2026 Q1	$945K	Sell	153,610 -46,139	-23%	-$356K	﹤0.01%	7789
2025 Q4	$1.54M	Buy	199,749 +92,253	+86%	+$757K	﹤0.01%	6451
2025 Q3	$1.01M	Buy	107,496 +60,713	+130%	+$526K	﹤0.01%	7531
2025 Q2	$388K	Buy	+46,783	New	+$320K	﹤0.01%	9213
2024 Q2	–	Sell	-48,714	Closed	-$542K	–	14593
2024 Q1	$542K	Buy	+48,714	New	+$489K	﹤0.01%	8206
2023 Q4	–	Sell	-13,710	Closed	-$114K	–	14574
2023 Q3	$103K	Sell	13,710 -25,616	-65%	-$208K	﹤0.01%	10860
2023 Q2	$347K	Buy	39,326 +4,056	+11%	+$33.7K	﹤0.01%	8717
2023 Q1	$293K	Buy	35,270 +7,216	+26%	+$66.9K	﹤0.01%	9419
2022 Q4	$269K	Buy	28,054 +12,378	+79%	+$110K	﹤0.01%	9550
2022 Q3	$127K	Buy	+15,676	New	+$108K	﹤0.01%	10878
2022 Q1	–	Sell	-14,874	Closed	-$65K	–	13893
2021 Q4	$65K	Buy	+14,874	New	+$111K	﹤0.01%	13090

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors's FENC Position: Q2 2026 in Review

Citadel Advisors reduced its Fennec Pharmaceuticals (FENC) stake by 54% in Q2 2026, selling an estimated $674K and leaving 71,032 shares worth $764K. The position accounts for ﹤0.01% of the portfolio, ranked #8863.

Citadel Advisors first reported a position in FENC in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.54M in Q4 2025. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Citadel Advisors held 71,032 shares of Fennec Pharmaceuticals worth $764K as of Q2 2026.
Citadel Advisors sold 82,578 Fennec Pharmaceuticals shares in Q2 2026, an estimated $674K.
Fennec Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8863 holding.
Citadel Advisors first reported a position in Fennec Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
Citadel Advisors's Fennec Pharmaceuticals position peaked at $1.54M in Q4 2025.
105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.